Reaction: EMA recommends approval of first vaccine in pregnancy to protect infants against RSV in the first six months of life
The European Medicines Agency (EMA) has recommended marketing authorisation in the European Union for Abrysvo vaccine to protect against respiratory syncytial virus (RSV) disease in infants up to six months of age. It is the first vaccine of its kind indicated for passive immunisation of newborns through administration to the mother during pregnancy. It is also indicated for people over 60 years of age. The European Commission now has to decide on its EU-wide marketing authorisation.